SKB264 binds TROP2 on tumor cells, is internalized, and releases tirumotecan, which inhibits DNA topoisomerase I to cause DNA damage and apoptosis. DNA topoisomerase I is the intracellular payload target, not the antigen that determines cell targeting; killing occurs mainly in TROP2+ cells (with potential bystander effect).